×
PAVM dropped -8.16% in regular-session trading, falling from the prior close of $1.47 to $1.35 by late morning on heavy two-way activity. No verified news or fundamental catalyst found for the move; the slide is likely a continued unwind of the speculative spike that followed the November 13 third-quarter report, where the stock jumped +24.43% in a single session before reversing sharply.
QTRX slid -27.62% on Wednesday, dropping from a $2.86 previous close to $2.07 by 11:22 ET, with the entire decline occurring during regular trading hours. The cause was an abrupt leadership exit: CEO and director Everett Cunningham resigned effective November 18 for another healthcare role, and Chief Commercial Officer Jim Gute was named interim CEO while the board searches for a permanent replacement.
IRIX fell from Tuesday's $0.6996 close to $0.50 by 11:05 a.m. ET Wednesday, a -28.57% drop, with the gap-down occurring during the regular session and extending Tuesday's after-hours slide. The catalyst was Tuesday's post-close third-quarter report: revenue of $10.16 million against roughly $12.6 million expected, a -19% year-over-year decline, a -$0.08 EPS loss versus -$0.04 consensus, and 2026 revenue guidance cut to $46-$48 million from $51-$53 million.
QSI jumped from $1.01 at Tuesday's close to $1.17 in Wednesday's regular session, a +15.84% gain as of mid-morning, with most of the move coming after the opening bell. The catalyst was a premarket release announcing single-molecule detection of all 20 amino acids in the Proteus development program, beating the year-end 2026 target — the gating milestone management had tied to the Q2 2027 launch.
Clinical adoption is the defining catalyst: PacBio's shift from research-oriented instrument sales toward recurring consumables revenue from clinical and hospital customers is expected to remain the primary driver of growth into 2026 and beyond. New chemistry lowers sequencing costs: The SparkNex and SPRQ-Nx chemistry rollout is designed to raise throughput and reduce per-genome costs, potentially expanding the addressable market and improving system utilization.
The central target of $2.70 is the arithmetic mean of six verified analyst price targets reviewed for this article, spanning a low of $2.00 to a high of $3.00. With Pacific Biosciences of California, Inc. (PACB) recently trading near $1.82, reaching $2.70 would require a gain of roughly 48% — a substantial move.
Upcoming catalyst: The full market launch of the VIRATA minimally invasive spinal implant system, expected to expand Orthofix's procedural footprint and strengthen its integrated spine platform. Strategic positioning: A diversified portfolio spanning spine fixation, bone growth therapies, biologics, limb reconstruction, and enabling technologies supports multiple independent growth vectors.
The central target of $11 is the arithmetic mean of four verified analyst price targets, rounded from $10.75. The analyst price target range runs from a low of $9 to a high of $13, reflecting a meaningful spread in views.
PACB has swung sharply in recent weeks, rallying on AI-driven genomics partnerships before giving back much of the gain, leaving its trailing 30-day move in the low single digits. Third-quarter 2026 revenue rose about 6% year over year to $40.6 million, while management narrowed full-year revenue guidance to $155 million–$160 million.
Orthofix Medical (OFIX) shares declined roughly 30% over the past 30 days, falling from about $9.59 to a latest close near $6.67. The drop accelerated after third-quarter 2026 results, when management cut full-year revenue and adjusted EBITDA guidance.
The $2.75 target is not an analyst consensus . It is the published price objective of the single firm currently covering the stock, Alliance Global Partners, and is used here because there are too few analysts to form a meaningful average. At roughly $0.69, reaching $2.75 would require a gain of about 300%, a very large move.
Third quarter 2026 revenue declined 19% year over year to $10.2 million , well below consensus estimates of roughly $12.6 million. GAAP (generally accepted accounting principles) net loss was $1.4 million, or $0.08 per share , a wider loss than the approximately $0.04 per share analysts had projected.
The central $1.15 target reflects public discussion around the stock's pre-merger-announcement trading level rather than an analyst consensus; from a latest close near $0.54, it implies a very large move of roughly 113%. Only two dated analyst price targets remain in the public record — TD Cowen's $1.35 (Hold) and Jefferies' $1.75 (Buy), both from November 2025 — a range of $1.35 to $1.75 (mean about $1.55) that predates the merger and is shown for context only.
Standard BioTools reported third quarter 2026 revenue of $19.39 million , down about 1% year over year but above the consensus estimate of roughly $18.80 million. GAAP (Generally Accepted Accounting Principles) net income reached $13.48 million , a sharp swing from a $34.69 million net loss a year earlier, driven largely by a $30.0 million Illumina-related gain .
The central target examined here is $2.00 , a fallback objective derived from the stock's recent trading structure rather than an analyst consensus, representing roughly a 48% gain from the latest close of $1.35. The target is not an "average analyst price target." Only one published analyst price target is available — $7.00 from Loop Capital (June 2026) — which is too thin a sample to form a meaningful consensus and is therefore cited as context only.
The $22 central target used here is a publicly discussed price objective, not a current analyst consensus, because recent analyst targets cluster too close to the market price to be meaningful. The latest verified share price is approximately $18.10, so reaching $22 would require a roughly 21.5% advance.
Third-quarter revenue fell to $6.33 million , down 50.65% from $12.83 million a year earlier. The reported top line came in well below the roughly $15.1 million consensus estimate for the quarter.
Varex Imaging is expected to report results for the fourth quarter of fiscal year 2026 shortly, with Wall Street consensus pointing to adjusted earnings per share (EPS) of roughly $0.33 on revenue near $229.8 million. The projected figures compare against a strong prior-year quarter, when the company delivered non-GAAP EPS of $0.37 on revenue of $228.9 million, suggesting a roughly flat year-over-year top line and a modest decline in EPS.
ADGM fell -9.32% in regular-session trading Tuesday, dropping from Monday's $1.61 close to $1.4606 by 9:44 a.m. ET, hovering near its 52-week low. The drop extends Monday's -16.58% slide after the third-quarter 10-Q disclosed substantial doubt about the company's ability to continue as a going concern, with cash of $3.1 million, no revenue, and funding only into Q1 2027.
ITOC dropped -10.81% to $1.65 during Tuesday's regular session, down from the prior close of $1.85, extending a multi-week decline. No verified news or fundamental catalyst found; the slide is likely technical — profit-taking after a +33% rebound from $1.64 on Nov 5 to $2.18 on Nov 11, with four of the last five sessions closing lower — in a name that averages a 5.5% absolute daily swing.